Free Trial
→ June 12: Biggest IPO Ever? (From Brownstone Research) (Ad)tc pixel Free 4BB Stock Alerts

4basebio (4BB) Competitors

4basebio logo
GBX 550 +20.00 (+3.77%)
As of 11:50 AM Eastern
Compare

4BB vs. HZD, SCLP, VRP, BTG, and ARIX

Should you buy 4basebio stock or one of its competitors? MarketBeat compares 4basebio with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with 4basebio include Horizon Discovery Group plc (HZD.L) (HZD), Scancell (SCLP), Verona Pharma plc (VRP.L) (VRP), BTG (BTG), and Arix Bioscience (ARIX). These companies are all part of the "biotechnology" industry.

How does 4basebio compare to Horizon Discovery Group plc (HZD.L)?

Horizon Discovery Group plc (HZD.L) (LON:HZD) and 4basebio (LON:4BB) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, dividends, risk and media sentiment.

Horizon Discovery Group plc (HZD.L)'s return on equity of 0.00% beat 4basebio's return on equity.

Company Net Margins Return on Equity Return on Assets
Horizon Discovery Group plc (HZD.L)N/A N/A N/A
4basebio N/A -231.29%-54.30%

In the previous week, Horizon Discovery Group plc (HZD.L)'s average media sentiment score of 0.00 equaled 4basebio'saverage media sentiment score.

Company Overall Sentiment
Horizon Discovery Group plc (HZD.L) Neutral
4basebio Neutral

4basebio has a consensus price target of GBX 1,600, indicating a potential upside of 190.91%. Given 4basebio's stronger consensus rating and higher possible upside, analysts clearly believe 4basebio is more favorable than Horizon Discovery Group plc (HZD.L).

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Horizon Discovery Group plc (HZD.L)
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
4basebio
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

0.9% of 4basebio shares are held by institutional investors. 12.1% of 4basebio shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Horizon Discovery Group plc (HZD.L) has higher revenue and earnings than 4basebio. 4basebio is trading at a lower price-to-earnings ratio than Horizon Discovery Group plc (HZD.L), indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Horizon Discovery Group plc (HZD.L)£54.63M0.00N/A-£5.50N/A
4basebio£1.78M47.87-£9.84M-£99.00N/A

Summary

4basebio beats Horizon Discovery Group plc (HZD.L) on 6 of the 10 factors compared between the two stocks.

How does 4basebio compare to Scancell?

4basebio (LON:4BB) and Scancell (LON:SCLP) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, profitability, media sentiment, institutional ownership, dividends, valuation and risk.

4basebio has a beta of 1.09, indicating that its stock price is 9% more volatile than the broader market. Comparatively, Scancell has a beta of 0.573, indicating that its stock price is 43% less volatile than the broader market.

4basebio has a net margin of 0.00% compared to Scancell's net margin of -116.98%. Scancell's return on equity of 90.29% beat 4basebio's return on equity.

Company Net Margins Return on Equity Return on Assets
4basebioN/A -231.29% -54.30%
Scancell -116.98%90.29%-45.28%

0.9% of 4basebio shares are owned by institutional investors. Comparatively, 1.5% of Scancell shares are owned by institutional investors. 12.1% of 4basebio shares are owned by insiders. Comparatively, 15.5% of Scancell shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, 4basebio's average media sentiment score of 0.00 equaled Scancell'saverage media sentiment score.

Company Overall Sentiment
4basebio Neutral
Scancell Neutral

Scancell has higher revenue and earnings than 4basebio. Scancell is trading at a lower price-to-earnings ratio than 4basebio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
4basebio£1.78M47.87-£9.84M-£99.00N/A
Scancell£4.71M53.31-£6.75M-£0.55N/A

4basebio currently has a consensus target price of GBX 1,600, indicating a potential upside of 190.91%. Given 4basebio's stronger consensus rating and higher probable upside, research analysts clearly believe 4basebio is more favorable than Scancell.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
4basebio
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Scancell
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Summary

Scancell beats 4basebio on 8 of the 14 factors compared between the two stocks.

How does 4basebio compare to Verona Pharma plc (VRP.L)?

4basebio (LON:4BB) and Verona Pharma plc (VRP.L) (LON:VRP) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, earnings, dividends, valuation, risk and institutional ownership.

0.9% of 4basebio shares are held by institutional investors. 12.1% of 4basebio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

4basebio presently has a consensus price target of GBX 1,600, indicating a potential upside of 190.91%. Given 4basebio's stronger consensus rating and higher probable upside, equities research analysts clearly believe 4basebio is more favorable than Verona Pharma plc (VRP.L).

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
4basebio
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Verona Pharma plc (VRP.L)
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Verona Pharma plc (VRP.L) has lower revenue, but higher earnings than 4basebio. 4basebio is trading at a lower price-to-earnings ratio than Verona Pharma plc (VRP.L), indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
4basebio£1.78M47.87-£9.84M-£99.00N/A
Verona Pharma plc (VRP.L)N/AN/AN/A-£32.70N/A

In the previous week, 4basebio's average media sentiment score of 0.00 equaled Verona Pharma plc (VRP.L)'saverage media sentiment score.

Company Overall Sentiment
4basebio Neutral
Verona Pharma plc (VRP.L) Neutral

Verona Pharma plc (VRP.L)'s return on equity of 0.00% beat 4basebio's return on equity.

Company Net Margins Return on Equity Return on Assets
4basebioN/A -231.29% -54.30%
Verona Pharma plc (VRP.L) N/A N/A N/A

Summary

4basebio beats Verona Pharma plc (VRP.L) on 6 of the 10 factors compared between the two stocks.

How does 4basebio compare to BTG?

BTG (LON:BTG) and 4basebio (LON:4BB) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, risk, institutional ownership, earnings, analyst recommendations, valuation and dividends.

In the previous week, BTG had 4 more articles in the media than 4basebio. MarketBeat recorded 4 mentions for BTG and 0 mentions for 4basebio. 4basebio's average media sentiment score of 0.00 beat BTG's score of -0.15 indicating that 4basebio is being referred to more favorably in the news media.

Company Overall Sentiment
BTG Neutral
4basebio Neutral

BTG currently has a consensus price target of GBX 160, indicating a potential upside of 32.23%. 4basebio has a consensus price target of GBX 1,600, indicating a potential upside of 190.91%. Given 4basebio's higher possible upside, analysts plainly believe 4basebio is more favorable than BTG.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BTG
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00
4basebio
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

BTG has higher revenue and earnings than 4basebio. 4basebio is trading at a lower price-to-earnings ratio than BTG, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BTG£159.40M1.22N/A£6.0020.17
4basebio£1.78M47.87-£9.84M-£99.00N/A

BTG's return on equity of 0.00% beat 4basebio's return on equity.

Company Net Margins Return on Equity Return on Assets
BTGN/A N/A N/A
4basebio N/A -231.29%-54.30%

19.3% of BTG shares are held by institutional investors. Comparatively, 0.9% of 4basebio shares are held by institutional investors. 19.8% of BTG shares are held by company insiders. Comparatively, 12.1% of 4basebio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

BTG beats 4basebio on 9 of the 12 factors compared between the two stocks.

How does 4basebio compare to Arix Bioscience?

Arix Bioscience (LON:ARIX) and 4basebio (LON:4BB) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, dividends, institutional ownership, media sentiment, analyst recommendations and earnings.

41.3% of Arix Bioscience shares are held by institutional investors. Comparatively, 0.9% of 4basebio shares are held by institutional investors. 20.7% of Arix Bioscience shares are held by company insiders. Comparatively, 12.1% of 4basebio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Arix Bioscience has a net margin of 105.64% compared to 4basebio's net margin of 0.00%. Arix Bioscience's return on equity of 6.41% beat 4basebio's return on equity.

Company Net Margins Return on Equity Return on Assets
Arix Bioscience105.64% 6.41% 2.18%
4basebio N/A -231.29%-54.30%

4basebio has a consensus target price of GBX 1,600, indicating a potential upside of 190.91%. Given 4basebio's stronger consensus rating and higher possible upside, analysts clearly believe 4basebio is more favorable than Arix Bioscience.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Arix Bioscience
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
4basebio
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

Arix Bioscience has a beta of 1.05, indicating that its stock price is 5% more volatile than the broader market. Comparatively, 4basebio has a beta of 1.09, indicating that its stock price is 9% more volatile than the broader market.

Arix Bioscience has higher revenue and earnings than 4basebio. 4basebio is trading at a lower price-to-earnings ratio than Arix Bioscience, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Arix Bioscience£14.16M0.00£14.96M£0.11N/A
4basebio£1.78M47.87-£9.84M-£99.00N/A

In the previous week, Arix Bioscience's average media sentiment score of 0.00 equaled 4basebio'saverage media sentiment score.

Company Overall Sentiment
Arix Bioscience Neutral
4basebio Neutral

Summary

Arix Bioscience beats 4basebio on 9 of the 13 factors compared between the two stocks.

Get 4basebio News Delivered to You Automatically

Sign up to receive the latest news and ratings for 4BB and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding 4BB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

4BB vs. The Competition

Export
Metric4basebioBiotechnology IndustryMedical SectorLON Exchange
Market Cap£85.17M£477.14M£6.31B£2.80B
Dividend YieldN/A3.86%2.68%6.07%
P/E Ratio-5.563.1421.13365.58
Price / Sales47.876,915.55546.6688,236.04
Price / Cash16.0813.1327.4427.89
Price / Book-13.4184.899.957.74
Net Income-£9.84M-£96.07M£3.56B£5.89B
7 Day Performance5.77%1.82%2.19%0.93%
1 Year Performance-51.28%96.44%36.31%79.20%

4basebio Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
4BB
4basebio
N/AGBX 550
+3.8%		GBX 1,600
+190.9%		-53.1%£85.17M£1.78MN/A101
HZD
Horizon Discovery Group plc (HZD.L)
N/AN/AN/AN/A£302.98M£54.63MN/A416
SCLP
Scancell
N/AGBX 23.90
-2.4%		N/A+130.9%£248.03M£4.71MN/A51
VRP
Verona Pharma plc (VRP.L)
N/AN/AN/AN/A£228MN/AN/A22
BTG
BTG
4.1236 of 5 stars		GBX 121
+0.4%		GBX 160
+32.2%		N/A£194.08M£159.40M20.174,690

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:4BB) was last updated on 6/1/2026 by MarketBeat.com Staff.
From Our Partners
The 1934 playbook
In 1934, a legal government maneuver transferred billions in wealth overnight. Most Americans never saw it com...
American Alternative | Sponsoredtc pixel
$30 stock to buy before Starlink goes public (WATCH NOW!)
In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...
Paradigm Press | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
June 12: $100 Turns Into $100,000?
The SpaceX IPO is scheduled for June 12, and former tech executive Jeff Brown - who identified Bitcoin, Tesla,...
Brownstone Research | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
SpaceX just filed. The clock is ticking.
Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...
The Oxford Club | Sponsoredtc pixel
SpaceX will mint billionaires. You won't be one of them.
By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...
Behind the Markets | Sponsoredtc pixel